Get started
Author

Abdüssamet Çelebi

Observed names: A Celebi, A. Celebi, Abdussamed Çelebi, Abdussamet Celebi, Abdussamet Celebı, Abdussamet ÇELEBİ, Abdussamet Çelebi, Abdüssamed Çelebi, abdüssamet çelebi
ORCID: 0000-0002-6922-1018
Observed ORCID: 0000-0002-6922-1018
OpenAlex ID: A5035460759
The effect of low HER2 expression on treatment outcomes in metastatic hormone receptor positive breast cancer patients treated with a combination of a CDK4/6 inhibitor and endocrine therapy: A multicentric retrospective study
2023 · Eda Caliskan Yildirim, Elif Atag, et al. · The Breast · 25
PDF
Efficacy of subsequent treatments in patients with hormone-positive advanced breast cancer who had disease progression under CDK 4/6 inhibitor therapy
2023 · Cengiz Karacin, Berna Oksuzoglu, et al. · BMC Cancer · 24
PDF
Clinical outcomes of cyclin-dependent kinase 4–6 (CDK 4–6) inhibitors in patients with male breast cancer: A multicenter study
2022 · Hasan Çağrı Yıldırım, Emel Mutlu, et al. · The Breast · 22
Treatment outcomes and prognostic factors in patients with driver mutant non-small cell lung cancer and de novo brain metastases
2024 · Seda Kahraman, Serdar Karakaya, et al. · Scientific Reports · 20
Prognostic Factors in High Grade Osteosarcoma Patients Who Received Neoadjuvant Therapy and Subsequently Underwent Surgery: Data from the Turkish Oncology Group
2025 · Nadiye Sever, Fatih Şimşek, et al. · Journal of Clinical Medicine · 19
Evaluation of Dose Reduction Factors and Impact on Progression-Free Survival in Patients Treated with CDK 4/6 Inhibitors
2025 · Ali Kaan Güren, Murad Guliyev, et al. · Journal of Clinical Medicine · 12
PDF
Prognostic Nutritional Index as a Biomarker in Metastatic Hormone‐Sensitive Prostate Cancer: Impact on Survival and Treatment Optimization
2025 · Muhammet Bekir Hacioglu, Ahmet Kucukarda, et al. · The Prostate · 10
PDF
The efficacy of palbociclib and ribociclib in the first-line treatment of metastatic hormone receptor-positive, human epidermal growth factor receptor 2-negative breast cancer in male patients: a Turkish oncology group (TOG) study
2024 · Hasan Çağrı Yıldırım, Yasin Kutlu, et al. · International Journal of Clinical Oncology · 10
Impact of renin angiotensin system inhibitors on survival of patients with metastatic non-small cell lung cancer.
2025 · Nadiye Sever, Emil Yunusov, et al. · PubMed Central · 9
PDF
Age-adjusted Charlson Comorbidity Index is a valuable prognostic tool in operable soft tissue sarcoma of trunk and extremities
2022 · Tugba Akin Telli, Ozkan Alan, et al. · Orthopaedics & Traumatology Surgery & Research · 8
Clinical Outcomes of CDK4/6 Inhibitor Therapy in HR+/HER2− Metastatic Breast Cancer: A Multicenter Comparison of HER2‐Low and HER2‐Zero Subgroups
2025 · Erkan Ozcan, Ivo Gokmen, et al. · The Breast Journal · 5
PDF
HER2 exon 20 mutant non-small cell lung cancer with complete remission of intracranial metastases with trastuzumab deruxtecan: a case report
2024 · Ali Kaan Güren, Erkam Kocaaslan, et al. · Anti-Cancer Drugs · 5
Evaluation of Predictive and Prognostic Importance of Lung Immune Prognostic Index in Locally Advanced Rectal Cancer Patients Treated With Neoadjuvant Chemoradiotherapy
2023 · Rukiye Arıkan, Hilal Alkış, et al. · Cureus · 5
PDF
Tamoxifen or aromatase inhibitors: which one is the culprit of urinary incontinence in premenopausal breast cancer patients receiving adjuvant hormone therapy?
2023 · Kubilay Karaboyun, Eyyup Cavdar, et al. · Supportive Care in Cancer · 5
Correction: Efficacy of subsequent treatments in patients with hormone-positive advanced breast cancer who had disease progression under CDK 4/6 inhibitor therapy
2023 · Cengiz Karacin, Berna Oksuzoglu, et al. · BMC Cancer · 5
PDF
The Role of Baseline PET/CT Parameters in Predicting Treatment Response in Patients with Locally Advanced Rectal Cancer Undergoing Total Neoadjuvant Therapy
2025 · Ali Kaan Güren, Zilan Başkan, et al. · Medicina · 4
PDF
PNI as a Potential Add-On Biomarker to Improve the IMDC Intermediate Prognostic Score
2023 · İbrahim Vedat Bayoğlu, Javid Hüseynov, et al. · Journal of Clinical Medicine · 4
PDF
Impact of Skeletal Muscle Measurements by Chest Computed Tomography on Survival and Postoperative Complications in Patients with Soft Tissue Sarcoma
2022 · Tugba Akin Telli, Onur Bugdayci, et al. · Nutrition and Cancer · 4
Clinicopathologic Features and Efficacy of Induction Chemotherapy in Nasopharyngeal Carcinoma: Real-World Experience
2024 · Nargiz Majidova, Murat Sarı, et al. · Oncology Research and Treatment · 3
PDF
Comparison of the Efficacy and Safety of 3 Months of CAPOX Followed by 3 Months of Capecitabine and 6 Months of CAPOX/FOLFOX in the Adjuvant Treatment of Low-Risk Stage III Colon Cancer Treated Surgically
2023 · Murat Bardakci, Derya Demirtas Esmer, et al. · Oncology · 3
Prognostic significance of 18F-FDG PET/CT indices in metastatic renal cell cancer and evaluation of revised IMDC risk model by including 18F-FDG PET-CT parameters
2022 · Rukiye Arikan, Salih Ozguven, et al. · Acta Radiologica · 3
Acquired CD74–ROS1 fusion–mediated osimertinib resistance successfully treated with osimertinib and crizotinib: a case report
2026 · Ali Kaan Güren, Erkam Kocaaslan, et al. · Journal of Chemotherapy · 2
Prognostic Value of Systemic Immune-Inflammation Index in Mucosal Malignant Melanoma
2026 · Burak Paçacı, Erkam Kocaaslan, et al. · Journal of Clinical Medicine · 2
PDF
Adult-Onset Diffuse Midline Glioma, H3K27-Altered: A Genomics-Guided, Individualized, Multimodal Treatment Approach
2026 · Abdussamet Çelebi, Bilal Yıldırım, et al. · Brain Sciences · 2
PDF
Prognostic Value of Treatment-Related Body Composition Changes in Metastatic NSCLC Receiving Nivolumab
2026 · Erkam Kocaaslan, Ali Kaan Güren, et al. · Medicina · 2
PDF
Works count: 73
Citation count: 229
H-index: 9
I10-index: 8
Year
Topic
Type